Skip to main content

Ribociclib User Reviews & Ratings (Page 2)

Brand names: Kisqali

Ribociclib has an average rating of 8.3 out of 10 from a total of 30 reviews on Drugs.com. 81% of reviewers reported a positive experience, while 7% reported a negative experience.

Reviews for Ribociclib

  • Cara
  • Taken for 6 months to 1 year
  • October 1, 2021

Kisqali (ribociclib) for Breast Cancer, Metastatic "Kisqali worked at first. All my numbers went down. Then they spiked up all at once."

3 / 10
Was this helpful?YesNo
21 Report
  • Anonymous
  • Taken for less than 1 month
  • February 26, 2021

Kisqali (ribociclib) for Breast Cancer, Metastatic "With Breast Cancer, Metastasis I am feeling very much better, while using Kisqali. But do have body pains but that can be manageable. Now I can easily run my job and home affairs."

8 / 10
Was this helpful?YesNo
22 Report
  • Samy
  • Taken for less than 1 month
  • December 4, 2019

For Breast Cancer, Metastatic "I have taken ribociclib for less than 10 days and develop a severe infection and very low white cells so I had to stay at hospital for 10 days to clear my infection"

Was this helpful?YesNo
3 Report
  • 123
  • Taken for 1 to 6 months
  • November 25, 2022

For Breast Cancer "2 cycles & tumour is spreading ....efficacy of drug not known"

1 / 10
Was this helpful?YesNo
1 Report
  • Anonymous
  • Taken for 6 months to 1 year
  • July 18, 2024

Kisqali (ribociclib) for Breast Cancer, Metastatic "Very few side effects. Have been able to continue golf, pickleball, bridge, and a nice social life. 600 mg per day for 3 weeks, then one week off."

10 / 10
Was this helpful?YesNo
0 Report

Reviews may be edited to correct grammar/spelling or to remove inappropriate language and content. Reviews that appear to be created by parties with a vested interest are not published. This information is not intended to endorse any particular medication. While these reviews may be helpful, they are not a substitute for the expertise, knowledge, and judgement of healthcare professionals.